Antifibrotic effects of CXCR4 antagonist in bleomycin-induced pulmonary fibrosis in mice

• DOI: 10.2152/jmi.60.127
• Publication Date: 2015-06-18T22:06:12Z
• Authors: Hideki Makino; Yoshinori Aono; Momoyo Azuma; Masami Kishi; Yuki Yokota; Katsuhiro Kinoshita; Akio Takezaki; Jun Kishi; Hiroshi Kawano; Hirohisa Ogawa; Hisanori Uehara; Keisuke Izumi; Saburo Sone; Yasuhiko Nishioka
• Keywords: Fibrocyte

Circulating fibrocytes had been reported to migrate into the injured lungs, and contribute fibrogenesis via chemokine-chemokine receptor systems including CXCL12-CXCR4 axis. Here we hypothesized that blockade of CXCR4 might inhibit migration lungs subsequent pulmonary fibrosis. To explore antifibrotic effects CXCR4, used a specific antagonist for AMD3100, in bleomycin-induced fibrosis model mice. Administration AMD3100 significantly improved loss body weight mice treated with bleomycin, inhibited fibrotic lesion subpleural areas lungs. The quantitative analysis demonstrated treatment reduced collagen content score (Aschcroft score) Although did not affect cell classification bronchoalveolar lavage fluid on day 7, percentage lymphocytes was by 14. directly human response CXCL12 vitro, trafficking bleocmycin vivo. These results suggest be useful strategy therapy patients inhibiting circulating fibrocytes. J. Med. Invest. 60: 127-137, February, 2013